natgillin/translations-raw huggingface dataset:
The frequency of adverse reactions listed below is defined using the following convention: Very common (≥1/10); common (≥1/100 to &lt; 1/10); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data):
Učestalost niže navedenih nuspojava definirana je pomoću sljedeće konvencije: Vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency of adverse reactions listed below is defined using the following convention: very common ( 1/10); common ( 1/100 to &lt; 1/10); uncommon ( 1/1,000 to &lt; 1/100); rare ( 1/10,000 to
Učestalost dolje navedenih nuspojava definirana je na sljedeći način: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do
The frequency of all of the adverse reactions in vascular surgery was uncommon (defined as &gt; 1/1000, &lt; 1/100).
Pri vaskularnim kirurškim zahvatima učestalost svih nuspojava bila je manje česta (definirano kao (≥1/1 000 &lt; 1/100).
The frequency of hypersensitivity reactions (very rare, &lt; 1/10,000) has been deduced from post-marketing surveillance.
Učestalost reakcija preosjetljivosti (vrlo rijetko, &lt; 1/10 000) utvrđena je praćenjem nakon stavljanja lijeka u promet.
The frequency of notable QTcF intervals [i.e. &gt; 450 ms (males) and &gt; 470 ms (females)] and reports of hypokalaemia were similar to placebo.
Učestalost upadljivih QTcF intervala [tj. &gt; 450 ms (muškarci) i &gt; 470 ms (žene)] i hipokalijemije bila je slična kao za placebo.
The frequency of patients with major hypoglycaemic events was low ( &lt; 1%) and similar for empagliflozin and placebo as add-on to metformin, and for the combination of empagliflozin with metformin in drug-naïve patients compared to those treated with empagliflozin and metformin as individual components.
Učestalost bolesnika s događajima teške hipoglikemije bila je niska ( &lt; 1 %) i slična uz empagliflozin i placebo kao dodatkom metforminu, te u prethodno neliječenih bolesnika koji su primali kombinaciju empagliflozina i metformina u usporedbi s bolesnicima liječenim empagliflozinom i metforminom kao pojedinačnim komponentama.
The frequency of PBA episodes as measured by “Count of Episodes” in both NUEDEXTA treatment groups decreased significantly throughout the course of the study by an incremental reduction of 47% and 49% relative to placebo, respectively (p &lt; 0.0001 for both comparisons).
Učestalost epizoda pseudobulbarnog afekta mjerena kao „broj epizoda“ u obje skupine liječene NUEDEXTOM značajno se smanjila tijekom trajanja ispitivanja, postupnim smanjenjem od 47% odnosno 49% u odnosu na placebo (p &lt; 0,0001 za obje usporedbe).
The frequency of possible side effects listed below is defined using the following convention: Very common (1/10), Common (1/100 to &lt; 1/10), Uncommon (1/1,000 to &lt; 1/100), Not known (cannot be estimated from available data).
Učestalost mogućih nuspojava navedenih u nastavku definirana je na sljedeći način: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency of reported nocturia was comparable between placebo and empagliflozin ( &lt; 1%).
Učestalost prijavljene nokturije je bila usporediva između placeba i empagliflozina ( &lt; 1 %).
The frequency of reported nocturia was similar for placebo and empagliflozin ( &lt; 1%).
Učestalost prijavljene nokturije je bila slična za placebo i empagliflozin ( &lt; 1%).
The frequency of side effects is defined by the following convention: very common (≥1/10), common (≥1/100 to ≤1/10), uncommon (≥1/1,000 to ≤1/100), rare (≥1/10,000 to ≤1/1,000), very rare (≤1/10,000), and not known (cannot be estimated from the available data).
Učestalost nuspojava definirana je sljedećom konvencijom: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se utvrditi iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10 ), common (≥ 1/100 to &lt; 1/10).
Navedene učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to
Navedene učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10%), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1 000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1 000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 and &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1 000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1 000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to
Navedene učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1 000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1 000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10).
Navedene učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10).
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥ 1/100 to &lt; 1/10 %), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000% and &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1 000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1 000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
The geometric mean of the AUC0-inf was 18726 ng•h/mL in the non-smokers and 6718 ng•h/mL in the smokers with a mean ratio of 35.9% (95% CI: 23.7 to 54.3, p &lt; 0.0001).
Geometrijska sredina AUC0-inf iznosila je 18726 ngh/ml u nepušača i 6718 ngh/ml u pušača, uz srednji omjer od 35,9% (95% CI: 23,7 do 54,3, p &lt; 0,0001).
The geometric mean plasma Cmax was approximately 0.5 ng/ml (range 0 to 2.3), and the geometric mean plasma AUC was approximately 1.7 day* ng/ml (range &lt; LLOQ (lower limit of quantification) to 13.5).
Geometrijska srednja vrijednost plazmatske Cmax bila je približno 0,5 ng/ml (raspon od 0 do 2,3), a geometrijska srednja vrijednost plazmatskog AUC-a bila je približno 1,7 dan* ng/ml (raspon &lt; od donje granice mjerljivosti do 13,5).
The group of NS5A RAVs that conferred &gt; 100-fold shift and was observed in patients were the following substitutions in genotype 1a (M28A, Q30H/R/E, L31M/V/I, H58D, Y93H/N/C) or in genotype 1b (Y93H).
Skupinu NS5A RAV-ova koji su nosili povećanje &gt; 100 puta i koji su bili opaženi u pacijenata činile su sljedeće supstitucije u genotipu 1a (M28A, Q30H/R/E, L31M/V/I, H58D, Y93H/N/C) ili u genotipu 1b (Y93H).
The group with dapagliflozin sequentially added to saxagliptin and metformin achieved statistically significant (p-value &lt; 0.0001) greater reductions in HbA1c versus the group with placebo sequentially added to saxagliptin plus metformin group at 24 weeks (see table 4).
Skupina u kojoj je saksagliptinu i metforminu sekvencijski dodan dapagliflozin postigla je statistički značajno (p-vrijednost &lt; 0,0001) veća sniženja HbA1c u 24. tjednu nego skupina u kojoj je saksagliptinu plus metforminu sekvencijski dodan placebo (vidjeti tablicu 4).
The group with saxagliptin sequentially added to dapagliflozin and metformin achieved statistically significant (p-value &lt; 0.0001) greater reductions in HbA1c versus the group with placebo sequentially added to dapagliflozin plus metformin group at 24 weeks (see table 4).
Skupina u kojoj je dapagliflozinu i metforminu sekvencijski dodan saksagliptin postigla je statistički značajno (p-vrijednost &lt; 0,0001) veća sniženja HbA1c u 24. tjednu nego skupina u kojoj je dapagliflozinu plus metforminu sekvencijski dodan placebo (vidjeti tablicu 4).
The half life of tocilizumab in pJIA patients is up to 16 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 10 mg/kg for body weight &lt; 30 kg) during a dosing interval at steady state.
Poluvijek tocilizumaba kod bolesnika s pJIA iznosi najviše 16 dana u obje kategorije tjelesne težine (8 mg/kg za tjelesnu težinu ≥ 30 kg ili 10 mg/kg za tjelesnu težinu &lt; 30 kg) tijekom razdoblja doziranja u stanju dinamičke ravnoteže.
The half life of tocilizumab in sJIA patients is up to 23 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 12 mg/kg for body weight &lt; 30 kg) at week 12.
Poluvijek tocilizumaba je kod bolesnika sa sJIA iznosio najviše 23 dana u obje kategorije tjelesne težine (8 mg/kg za tjelesnu težinu ≥ 30 kg ili 12 mg/kg za tjelesnu težinu &lt; 30 kg) nakon 12 tjedana.
The half-life of lenalidomide increased from approximately 3.5 hours in subjects with creatinine clearance &gt; 50 mL/min to more than 9 hours in subjects with reduced renal function &lt; 50 mL/min.
Poluvijek lenalidomida povećao se od približno 3,5 sata u ispitanika s klirensom kreatinina &gt; 50 mL/min na više od 9 sati u ispitanika sa smanjenom funkcijom bubrega &lt; 50 mL/min.
The hard capsules are green/white hard gelatin capsules imprinted ‘TMZ’ on cap &amp; ‘5’ on body.
Tvrde kapsule su zeleno/bijele tvrde želatinske kapsule s otisnutom oznakom ˝TMZ˝ na kapici i ˝5˝ na tijelu.
The hard capsules are maroon/white, hard gelatin capsules, imprinted with ‘TMZ’ on cap &amp; ‘180’ on body.
Tvrde kapsule su smeđe/bijele tvrde želatinske kapsule s otisnutom oznakom ˝TMZ˝ na kapici i ˝180˝ na tijelu.
The hard capsules are white/white, hard gelatin capsules imprinted with ‘TMZ’ on cap &amp; ‘250’ on body.
Tvrde kapsule su bijelo/bijele tvrde želatinske kapsule s otisnutom oznakom ˝TMZ˝ na kapici i ˝250˝ na tijelu.
The hardcapsules are yellow/ white hard gelatin capsules, imprinted ‘TMZ’ on cap &amp; ‘20’ on body.
Tvrde kapsule su žuto/bijele tvrde kapsule s otisnutom oznakom ˝TMZ˝ na kapici i ˝20˝ na tijelu.
The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR = 1.33 – 1.91) with a log-rank p &lt; 0.0001 in favour of the TMZ arm.
Omjer hazarda (engl. hazard ratio, HR) za ukupno preživljenje iznosio je 1,59 (95 % CI za HR = 1,33 - 1,91), uz log-rang p &lt; 0,0001 u korist skupine koja je primala TMZ.
The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR = 1.33 – 91) with a log-rank p &lt; 0.0001 in favour of the TMZ arm.
Omjer hazarda (engl. hazard ratio, HR) za ukupno preživljenje iznosio je 1,59 (95 % CI za HR = 1,33 - 1,91), uz log-rang p &lt; 0,0001 u korist skupine koja je primala TMZ.
The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR=1.33 -1.91) with a log-rank p &lt; 0.0001 in favour of the TMZ arm.
Omjer hazarda (engl. hazard ratio, HR) za ukupno preživljenje iznosio je 1,59 (95% CI za HR = 1,33-1,91), uz log-rang p &lt; 0,0001 u korist skupine koja je primala TMZ.
The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR=1.33-1.91) with a log-rank p &lt; 0.0001 in favour of the TMZ arm.
Omjer hazarda (HR) za ukupno preživljenje iznosio je 1,59 (95 % CI za HR = 1,33-1,91), uz log-rang p &lt; 0,0001 u korist skupine koja je primala TMZ.
The hazard ratio (HR) for overall survival was 1.59 (95% CI for HR=1.33 -1.91) with a log-rank p &lt; 0.0001 in favour of the TMZ arm.
Omjer hazarda (engl. hazard ratio, HR) za ukupno preživljenje iznosio je 1,59 (95% CI za HR = 1,33-1,91), uz log-rang p &lt; 0,0001 u korist skupine koja je primala TMZ.
The hazard ratio (HR) for overall survival was 1.59 (95% CI for HR=1.33 -1.91) with a log-rank p &lt; 0.0001 in favour of the TMZ arm.
Omjer hazarda (HR) za ukupno preživljenje iznosio je 1,59 (95% CI za HR = 1,33-1,91), uz log-rang p &lt; 0,0001 u korist skupine koja je primala TMZ.
The high volume of distribution (Vd) &gt; 2 l/kg bodyweight indicates good tissue penetration.
Visoki volumen distribucije (Vd) &gt; 2 l/kg tjelesne mase indicira dobro prodiranje u tkiva.
The high volume of distribution (Vd) &gt; 4 l/kg body weight indicates good tissue penetration.
Visok volumen raspodjele (Vd) &gt; 4 l/kg tjelesne mase ukazuje da je prodiranje u tkiva dobro.
The HR median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p = &lt; 0.01 to 0.03).
Medijan vremena do progresije bolesti prema ovim mjerama ishoda bio je za 0,7 do 2,1 mjeseca dulji u skupini koja je primala TMZ nego u skupini koja je primala prokarbazin (log-rang p = &lt; 0,01 do 0,03).
The IC50 for wild-type HXB2 is 0.24 to 0.6 M, while the IC50 for M184V containing HXB2 is &gt; 100 to 500 M.
IC50 za divlji soj HXB2 bila je 0,24 do 0,6 µM, dok je IC50 za M184V koja sadrži HXB2 bila &gt; 100 do 500 µM.
The immunogenicity and safety of ProQuad were evaluated in a clinical trial involving 799 subjects 4 through 6 years of age who had received Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. at least 1 month prior to study entry.
Imunogenost i sigurnost cjepiva ProQuad procijenili su se u kliničkom ispitivanju koje je uključilo 799 ispitanika u dobi od 4 do 6 godina koji su prethodno primili živo cjepivo protiv varičele (Oka/Merck) i cjepivo protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. najmanje 1 mjesec prije ulaska u ispitivanje.
The immunogenicity of a single dose of an earlier formulation of ProQuad was comparable to the immunogenicity of a single dose of its individual component vaccines (Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc.), currently used in routine vaccination in some countries.
Imunogenost jednokratne doze ranije formulacije cjepiva ProQuad bila je podjednaka imunogenosti jednokratne doze pojedinih komponenti cjepiva (živo cjepivo protiv varičele (Oka/Merck) i cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc.), koje se trenutno koriste za rutinsko cijepljenje u nekim zemljama.
The improved room temperature patch formulation showed better skin adhesion than the cold storage formulation with &gt; 90% of patches showing sufficient adhesion (i.e. &gt; 70% of the patch area adhering) compared to &lt; 83%.
Pokazalo se da poboljšana formulacija flastera koja se čuva na sobnoj temperaturi bolje prianja na kožu od formulacije flastera čuvanih na hladnom mjestu, s time da je ˃ 90 % flastera čuvanih na sobnoj temperaturi pokazalo dovoljno prianjanje (to znači da je više od 70 % površine flastera bilo nalijepljeno na kožu) u usporedbi s &lt; od 83 % kod flastera čuvanih na hladnom mjestu.
The improved room temperature patch formulation showed better skin adhesion than the cold storage formulation with &gt; 90% of patches showing sufficient adhesion (i.e. &gt; 70% of the patch area adhering) compared to &lt; 83%.
Pokazalo se da poboljšana formulacija flastera koja se čuva na sobnoj temperaturi bolje prianja na kožu od formulacije flastera čuvanih na hladnom mjestu, s time da je ˃ 90 % flastera čuvanih na sobnoj temperaturi pokazalo dovoljno prianjanje (to znači da je ˃ 70 % površine flastera bilo nalijepljeno na kožu) u usporedbi s &lt; 83 % kod flastera čuvanih na hladnom mjestu.
The improvement in the proportion of patients who achieved SVR was consistent across all subgroups in the randomisation strata (baseline platelet counts ( &lt; 50,000 vs. &gt; 50,000), viral load ( &lt; 800,000 IU/ml vs. ≥ 800,000 IU/ml) and genotype (2/3 vs.
Poboljšanje u udjelu bolesnika koji su postigli SVR bilo je konzistentno kroz sve podskupine u randomizacijskom stratumu (početni broj trombocita ( &lt; 50 000 nasuprot &gt; 50 000), količina virusa ( &lt; 800 000 IU/ml nasuprot 800 000 IU/ml) i genotip (2/3 nasuprot 1/4/6)).
The incidence in older, predominantly non-vaccinated children ( &gt; 5 years) did not change over the duration of the study.
Učestalost u starije, uglavnom necijepljene djece ( &gt; 5 godina) nije se mijenjala tijekom trajanja ispitivanja.
The incidence of a FEV1 reduction &gt; 15% from baseline after Rapiscan administration was assessed in three randomised, controlled clinical studies.
Incidencija smanjenja FEV1 &gt; 15% od početnih vrijednosti nakon primjene Rapiscana procjenjivana je u tri randomizirana kontrolirana klinička ispitivanja.
The incidence of a QTcF interval &gt; 500 msec was uncommon and observed in one patient (1/321 patients).
Incidencija intervala QTcF &gt; 500 ms bila je manje česta i opažena u jednog bolesnika (1/321 bolesnika).
The incidence of ADRs of all grades and grade 3 /4 ADR was similar in elderly patients compared to younger patients ( &lt; 65 years).
Incidencija nuspojava svih stupnjeva i nuspojava na lijek stupnja 3/4 bila je slična u starijih bolesnika i mlađih bolesnika ( &lt; 65 godina).
The incidence of ADRs of all grades and grade 3 /4 ADR was similar in elderly patients compared to younger patients ( &lt; 65 years).
Incidencija nuspojava svih stupnjeva i nuspojava stupnja 3/4 bila je slična u starijih i mlađih bolesnika ( &lt; 65 godina).
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N = 519), and compared to patients who received &gt; 6 cycles of pemetrexed (N = 281).
Incidencija nuspojava ocijenjena je u bolesnika koji su primili ≤ 6 ciklusa pemetrekseda kao terapije održavanja (N = 519) te je uspoređena s bolesnicima koji su primili &gt; 6 ciklusa pemetrekseda (N = 281).
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N=519), and compared to patients who received &gt; 6 cycles of pemetrexed (N=281).
Incidencija nuspojava ocijenjena je u bolesnika koji su primili ≤ 6 ciklusa pemetrekseda kao terapije održavanja (N=519) te je uspoređena s bolesnicima koji su primili &gt; 6 ciklusa pemetrekseda (N=281).
The incidence of adverse reactions was evaluated for patients who received ≤6 cycles of pemetrexed maintenance (N=519), and compared to patients who received &gt; 6 cycles of pemetrexed (N=281).
Incidencija nuspojava ocijenjena je u bolesnika koji su primili ≤ 6 ciklusa pemetrekseda kao terapije održavanja (N=519) te je uspoređena s bolesnicima koji su primili &gt; 6 ciklusa pemetrekseda (N=281).
The incidence of aminotransferase elevations (ALT/AST) &gt; 3 × ULN was 3.4% on macitentan 10 mg and 4.5% on placebo in a double-blind study in patients with PAH.
Incidencija povišenja aminotransferaza (ALT/AST) &gt; 3 × GGN iznosila je 3,4% za skupinu koja je primala macitentan 10 mg i 4,5% za skupinu koja je primala placebo u dvostruko slijepom ispitivanju u bolesnika s PAH-om.
The incidence of binding antibodies (excluding predose positive patients) was 1% as detected by the acid-dissociation ELISA and &lt; 1% as detected by the Biacore assay;
Incidencija vežućih protutijela (isključujući bolesnike pozitivne prije primjene prve doze) bila je 1%, detektiranih kiselinsko-disocirajućim testom ELISA i &lt; 1% detektirano testom Biacore;
The incidence of each thromboembolic component of the primary outcome was also significantly reduced in fondaparinux patients as follows: symptomatic PE [0 (0%) vs 5 (0.3%) (p=0.031)], symptomatic DVT [3 (0.2%) vs 18 (1.2%); relative risk reduction 83.4% (p &lt; 0.001)], symptomatic superficial-vein thrombosis extension [4 (0.3%) vs 51 (3.4%); relative risk reduction 92.2% (p &lt; 0.001)], symptomatic superficial-vein thrombosis reoccurrence [5 (0.3%) vs 24 (1.6%); relative risk reduction 79.2% (p &lt; 0.001)].
Incidencija svake tromboembolijske komponente primarnog ishoda je također značajno smanjena u fondaparinuks skupini bolesnika kako slijedi: simptomatska PE [0 (0%) naspram 5 (0,3%) (p=0,031)], simptomatska DVT [3 (0,2%) naspram 18 (1,2%); relativna redukcija rizika od 83,4% (p &lt; 0,001)], simptomatsko proširenje (ekstenzija) tromboze površinske vene [4 (0,3%) vs 51 (3,4%); relativna redukcija rizika od 92,2% (p &lt; 0,001)], recidiv simptomatske tromboze površinske vene [5 (0,3%) vs 24 (1,6%); relativna redukcija rizika od 79,2% (p &lt; 0,001)].